Tags : Commercialize

Solasia Signs a License Agreement with Isofol to Develop and

Shots: Isofol to receive $100M as up front, development, regulatory and commercial milestones, and clinical development cost and is eligible to receive royalties on sales of the therapy and retain its right to the therapy in ROW Solasia will lead clinical development activities in Japan and will be responsible for registrational filing and approval in […]Read More

Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in

Shots: Alvotech will lead the development, registration, and supply of the biosimilars, while Teva will be exclusively commercializing the products in the US. Alvotech will receive upfront with subsequent milestone payments over the next several years The companies will share the profit from the commercialization of the biosimilars. The collaboration leverages Teva’s commercial presence and […]Read More

Eli Lilly Amends its 2013 Agreement with Chi-Med to Commercialize

Shots: Chi-Med to receive 70%-80% of Elunate sales in the form of royalties, manufacturing costs and service payments with no upfront regarding this amendment. Lilly will maintain the exclusive commercialization rights and will continue to consolidate the sales of Elunate in China while Chi-Med retains all rights to fruquintinib outside of China The agreement allows […]Read More

AstraZeneca Signs an Agreement with Daichii Sankyo to Develop and

Shots: Daichii Sankyo to receive $1B as upfront of which $350M is due upon execution, $325M after 12mos. and $325M after 24 mos., ~$5B as contingent payment including $1B as regulatory milestones, and $4B as commercial milestones, making a total deal value up to ~6B The companies will jointly develop and commercialize DS-1062 globally and […]Read More

Fresenius Kabi Signs an Agreement with Medec to Commercialize IDACIO

Shots: Fresenius Kabi and Medec collaborated to offer IDACIO as an additional therapy option for rheumatologists and dermatologists to treat rheumatic illnesses. From Jun 01, 2020, Medec’s will market the biosimilar therapy Last year, Fresenius Kabi launched IDACIO in the EU for arthritis and psoriasis. The collaboration offers patients and doctors new benefits and synergies […]Read More

Alnylam and Dicerna Collaborate to Develop and Commercialize RNAi Therapeutics

Shots: The collaboration will explore Alnylam’s ALN-AAT02 and Dicerna’s DCR-A1AT, each in P-I/II development for the treatment of alpha-1 liver disease. Dicerna will lead the global clinical development and commercialization (US only) of its DCR-A1AT and Alnylam’s ALN-AAT02 Post P-III completion, Alnylam retains an option to commercialize the selected candidate outside the US. If Alnylam […]Read More

Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies

Shots: Dragonfly to receive ~ $47.5M up front, equity investment, development & commercial milestones along with royalties on sales of approved therapies Merck to get an option to license exclusive IP rights for multiple candidates developed using Dragonfly’s TriNKET technology platform for new targets in oncology, infectious disease, and immune disorders Dragonfly’s TriNKET technology act […]Read More

Fosun Pharma Signs an Agreement with BioNTech to Develop and

Shots: BioNTech to receive $135M as up front, future investment & milestone payments and $50M as an equity investment for 1,580,777 ordinary shares in BioNTech. Fosun to get the rights to commercialize BNT162 in China while BioNTech retain all rights of the vaccine in ROW The companies will jointly conduct clinical studies of BNT162 in […]Read More